A personalized assessment helps ensure the safest, most effective approach for you
However, the intensity of this need varies considerably depending on age and life circumstances
Intriguingly, emerging evidence suggests that some newer agents such as ocrelizumab (a B cell-depleting monoclonal antibody) and siponimod (a sphingosine 1-phosphate receptor modulator with anti-inflammatory and neuroprotective properties) are beneficial in progressive MS, potentially with effects independent of suppressing acute inflammation (Montalban et al., 2017
Your treatment protocol is customized based on your lab results, health history, and specific goals
Rituximab depletes CD20-positive B cells
Manufacturing standards: Good manufacturing practice (GMP) compliance, or at minimum documented quality control processes, indicates more reliable products